References

1. Huret, B., et al., [Pyopneumothorax in rheumatoid arthritis]. Rev Mal Respir, 2017.
2. Das, S. and P. Padhan, An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management. J Pharmacol Pharmacother, 2017. 8 (3): p. 81-86.
3. Mori, S., et al., Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. Clin Rheumatol, 2017. 36 (12): p. 2673-2682.
4. Nagaraj, S., et al., Early Rheumatoid Arthritis Presentation, Treatment and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis. Arthritis Care Res (Hoboken), 2017.
5. Buttgereit, F., et al., Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis, 2002.61 (8): p. 718-22.
6. Chatzidionysiou, K., et al., Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. 2017.76 (6): p. 1102-1107.
7. Sharif, K., et al., Physical activity and autoimmune diseases: Get moving and manage the disease. Autoimmun Rev, 2017.
8. Scott, L.J., Tocilizumab: A Review in Rheumatoid Arthritis.Drugs, 2017. 77 (17): p. 1865-1879.
9. Singh, J.A., et al., Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev, 2011(2): p. Cd008794.
10. Gaitonde, P., L.M. Bozzi, and F.T. Shaya, Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey. Semin Arthritis Rheum, 2017.
11. van Steenbergen, H.W., et al., Preventing progression from arthralgia to arthritis: targeting the right patients. Nat Rev Rheumatol, 2017.
12. Lin, T.C., et al., Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. J Am Heart Assoc, 2017. 6 (11).
13. Turesson, C., Comorbidity in rheumatoid arthritis. Swiss Med Wkly, 2016. 146 : p. w14290.
14. Santos, H., et al., Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA. Acta Reumatol Port, 2017. 42 (4): p. 287-299.
15. Ceccarelli, F., et al., Remission in early, aggressive rheumatoid arthritis: a multicentre prospective observational Italian study ARPA (Artrite Reumatoide Precoce Aggressiva). Clin Exp Rheumatol, 2013. 31 (3): p. 341-9.
16. Burgers, L.E., K. Raza, and A.H. van der Helm-van Mil, Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives. RMD Open, 2019. 5 (1): p. e000870.
17. Coffey, C.M., et al., Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity. Mayo Clin Proc, 2019. 94 (11): p. 2241-2248.
18. van Mulligen, E., et al., Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis, 2019. 78 (6): p. 746-753.
19. Lee, Z.M., et al., Correlation of symptomatic enterovirus infection and later risk of allergic diseases via a population-based cohort study. Medicine (Baltimore), 2017. 96 (4): p. e5827.
20. Lathia, U., E.M. Ewara, and F. Nantel, Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. Patient Prefer Adherence, 2017. 11 : p. 1133-1142.
21. Chin-Hung Chen, V., et al., Factors affecting lumbar surgery outcome: A nation-wide, population-based retrospective study. J Affect Disord, 2017. 222 : p. 98-102.
22. Pedersen, J.K., et al., Mortality and its predictors in patients with rheumatoid arthritis: a Danish population-based inception cohort study. Scand J Rheumatol, 2018: p. 1-7.
23. Chang, K., et al., Smoking and rheumatoid arthritis. Int J Mol Sci, 2014. 15 (12): p. 22279-95.
24. Shafia, S., et al., Rheumatoid arthritis and genetic variations in cytokine genes: a population-based study in Kashmir Valley. Immunol Invest, 2014. 43 (4): p. 349-59.
25. Savage, E.M., et al., Does rheumatoid arthritis disease activity correlate with weather conditions? Rheumatol Int, 2015.35 (5): p. 887-90.
26. Quinn, M.A. and P. Emery, Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol, 2003. 21 (5 Suppl 31): p. S154-7.
27. Contreras-Yanez, I. and V. Pascual-Ramos, Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther, 2015. 17 : p. 177.
28. Ramiro, S., et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis, 2014. 73 (3): p. 529-35.
29. Hashimoto, M., et al., Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther, 2018. 20 (1): p. 165.
30. Grijalva, C.G., et al., Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA, 2011. 306 (21): p. 2331-9.
31. Smolen, J.S., et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis, 2017. 76 (6): p. 960-977.